Skip to main content
Year archive

Active Biotech — 2021 filings

All 48 regulatory filings released by Active Biotech (ACTI) in 2021, sourced directly from the official regulator.

48 Filings
2021 Period
2021 filings (48)
Filing Released Lang
Prekliniska data kring tasquinimod som presenterades vid ASH 2021 finns tillgängliga på Active Biotechs hemsida
Report Publication Announcement
2021-12-15 Swedish
Preclinical tasquinimod data presented at ASH 2021 available on Active Biotech’s website
Regulatory Filings
2021-12-15 English
Active Biotech's nomination committee appointed
Board/Management Information
2021-12-10 English
Active Biotechs valberedning utsedd
AGM Information
2021-12-10 Swedish
Första försökspersonen doserad i klinisk fas I-studie med laquinimod ögondroppar
Regulatory Filings
2021-12-10 Swedish
First subject dosed in phase I clinical study with eye-drop formulation of laquinimod
Regulatory Filings
2021-12-10 English
Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotech’s partner NeoTX at SITC 2021
Regulatory Filings
2021-11-30 English
Data som visar att naptumomab estafenatox förstärker CAR-T-cellers effekt presenterades av Active Biotechs partner NeoTX vid SITC 2021
Regulatory Filings
2021-11-30 Swedish
Active Biotechs partner NeoTX presenterar vid det årliga mötet i Society for Immunotherapy of Cancer (SITC)
Investor Presentation
2021-11-09 Swedish
Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Regulatory Filings
2021-11-09 English
New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
Regulatory Filings
2021-11-04 English
Nya prekliniska data kring tasquinimod kommer att presenteras på det årliga mötet i American Society of Hematology (ASH)
Regulatory Filings
2021-11-04 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report 9M 2021
2021-11-04 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report 9M 2021
2021-11-04 English
Regulatory Filings 2021
Regulatory Filings
2021-10-20 Swedish
Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-s
Regulatory Filings
2021-10-20 English
Active Biotech: Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US
Regulatory Filings
2021-10-03 English
Active Biotech: Utvecklingen av tasquinimod i multipelt myelom fortsätter i kombinationsbehandling efter att den inledande fasen av den pågående studien i USA slutförts
Regulatory Filings
2021-10-03 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report H1 2021
2021-08-05 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q2 2021
2021-08-05 English
Active Biotechs partner NeoTX kommer stå som värd för ett KOL-webbseminarium om att övervinna resistens mot checkpoint-hämmare
Regulatory Filings
2021-07-08 Swedish
Active Biotech’s partner NeoTX will host KOL webinar on overcoming check point Inhibitor resistance
Regulatory Filings
2021-07-08 English
Active Biotech provides status update of its clinical naptumomab project
Regulatory Filings
2021-07-05 English
Active Biotech ger statusuppdatering i sitt kliniska naptumomab-projekt
Investor Presentation
2021-07-05 Swedish
Årsstämma i Active Biotech AB
AGM Information
2021-05-19 Swedish
Annual General Meeting of Active Biotech AB
AGM Information
2021-05-19 English
Annual Report 2020
Annual Report FY 2020
2021-04-22 Swedish
Annual Report 2020
Annual Report FY 2020
2021-04-22 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-04-22 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-04-22 English
ACTIVE BIOTECH: NOTICE of ANNUAL GENERAL MEETING OF SHAREHOLDERS
AGM Information
2021-04-20 English
ACTIVE BIOTECH: KALLELSE TILL ÅRSSTÄMMA
AGM Information
2021-04-20 Swedish
Active Biotech och NeoTX tillkännager IND-godkännande från FDA för klinisk fas II-studie med naptumomab
Regulatory Filings
2021-04-19 Swedish
Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab
Regulatory Filings
2021-04-19 English
Antal aktier och röster i Active Biotech
Declaration of Voting Results & Voting Rights Announcements
2021-03-31 Swedish
Number of shares and votes in Active Biotech
Declaration of Voting Results & Voting Rights Announcements
2021-03-31 English
Antal aktier och röster i Active Biotech
Declaration of Voting Results & Voting Rights Announcements
2021-02-26 Swedish
Number of shares and votes in Active Biotech
Declaration of Voting Results & Voting Rights Announcements
2021-02-26 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q4 2020
2021-02-11 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q4 2020
2021-02-11 English
ACTIVE BIOTECH ENTERS INTO A MANUFACTURING AGREEMENT WITH FAMAR HEALTH CARE SERVICES FOR NEW FORMULATION OF LAQUINIMOD
Regulatory Filings
2021-02-04 English
ACTIVE BIOTECH INGÅR TILLVERKNINGSAVTAL MED FAMAR HEALTH CARE SERVICES FÖR NY FORMULERING AV LAQUINIMOD
Regulatory Filings
2021-02-04 Swedish
Active Biotech’s rights issue heavily oversubscribed
Share Issue/Capital Change
2021-01-26 English
Active Biotechs företrädesemission kraftigt övertecknad
Capital/Financing Update
2021-01-26 Swedish
Adjustment of period for trading in subscription rights and interim shares in Active Biotech’s rights issue
Regulatory Filings
2021-01-07 English
Justering av period för handel med teckningsrätter och BTA i Active Biotechs företrädesemission
Capital/Financing Update
2021-01-07 Swedish
Active Biotech publishes prospectus and certain new financial information included in the prospectus
Capital/Financing Update
2021-01-05 English
Active Biotech offentliggör prospekt och viss ny finansiell information som återfinns i prospektet
Capital/Financing Update
2021-01-05 Swedish